Theralase Technologies (TSE:TLT)
:TLT
Want to see TSE:TLT full AI Analyst Report?
TLT Stock Chart & Stats
C$0.28
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.28
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.15 - C$0.41
Previous CloseN/A
Volume127.37K
Average Volume (3M)121.23K
Market Cap
C$61.69M
Enterprise ValueC$61.97M
Total Cash (Recent Filing)C$182.91K
Total Debt (Recent Filing)C$458.05K
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding257,058,320
10 Day Avg. Volume149,922
30 Day Avg. Volume121,227
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)23.49
Price to Sales (P/S)51.16
P/FCF Ratio-12.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)C$1.25M
Bulls Say, Bears Say
Bulls Say
Low-to-moderate LeverageLow-to-moderate leverage reduces near-term balance-sheet risk and preserves financial flexibility, giving management more time to advance clinical programs and pursue partnerships without immediate refinancing. This supports sustaining operations over the medium term despite operating losses.
Focused Photomedicine NicheA clear focus on laser-based photomedicine and PDT oncology applications creates a specialized niche with higher technical barriers to entry, potential for clinical differentiation, and targeted regulatory pathways. That structural positioning can support durable competitive advantages if clinical progress continues.
Easing Cash Burn TrendWhile still negative, the reduction in cash burn versus the 2022 trough suggests better cost control or operational progress. Improved cash consumption extends runway, lowers immediate financing pressure, and provides additional time to commercialize products or secure strategic partnerships.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates ongoing cash burn that erodes liquidity and forces reliance on external funding. This limits the company's ability to self-fund R&D and commercialization, increases dilution and refinancing risk, and constrains long-term strategic options.
Declining And Inconsistent RevenueA downward and inconsistent top-line trend shows weak commercial traction and limited scalability of current offerings. Falling revenue undermines operating leverage, reduces ability to absorb fixed R&D and regulatory costs, and makes achievement of sustainable profitability more uncertain without new revenue drivers.
Deep, Structural LossesVery large net losses relative to revenue and sharply negative margins have materially reduced equity and demonstrate the business is not yet generating positive returns. Persistent unprofitability drains capital, impedes reinvestment, and raises the risk of dilution or strategic restructuring if profitable pathways aren't established.
Theralase Technologies News
TLT FAQ
What was Theralase Technologies’s price range in the past 12 months?
Theralase Technologies lowest stock price was C$0.14 and its highest was C$0.41 in the past 12 months.
What is Theralase Technologies’s market cap?
Theralase Technologies’s market cap is C$61.69M.
When is Theralase Technologies’s upcoming earnings report date?
Theralase Technologies’s upcoming earnings report date is May 28, 2026 which is in 7 days.
How were Theralase Technologies’s earnings last quarter?
Currently, no data Available
Is Theralase Technologies overvalued?
According to Wall Street analysts Theralase Technologies’s price is currently Overvalued.
Does Theralase Technologies pay dividends?
Theralase Technologies does not currently pay dividends.
What is Theralase Technologies’s EPS estimate?
Theralase Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theralase Technologies have?
Theralase Technologies has 257,058,320 shares outstanding.
What happened to Theralase Technologies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Theralase Technologies?
Currently, no hedge funds are holding shares in TSE:TLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Theralase Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.63%
12-Months-Change
Fundamentals
Return on Equity
-314.74%
Trailing 12-Months
Asset Growth
7.63%
Trailing 12-Months
Company Description
Theralase Technologies
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.
Technical Analysis
Aurora Spine
―
Imagin Medical
―
Perimeter Medical Imaging AI
―
Profound Medical
―
VentriPoint Diagnostics
―
Options Prices
Currently, No data available
---